Teva Pharmaceutical Industries Ltd
TEVA- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000818686
In the last 90 days, Teva Pharmaceutical Industries Ltd insiders filed 0 open-market purchases and 8 sales; 675 institutions reported holding it in 13F filings for Q2 2026, worth $24.7B in total; 3 superinvestors hold it, including Greenlight Capital and Duquesne Family Office.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Teva Pharmaceutical Industries Ltd insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 8 filings
- 8 insiders, $17.0M in total
- Insiders trading
- 8
- Net value
- −$17.0M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Teva Pharmaceutical Industries Ltd, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Savage Brian | Interim Chief Legal Officer | 8,500 | Sep 22, 2026 | 4 |
| Mignone Roberto | Director | 0Indirect | Sep 22, 2026 | 6 |
| Weiss Amir | Chief Accounting Officer | 13,071 | Aug 25, 2026 | 7 |
| Satchi-Fainaro Ronit | Director | 111,986 | Aug 25, 2026 | 3 |
| Lippman Evan | EVP, Business Development | 25,591 | Aug 19, 2026 | 3 |
| Zaks Tal Zvi | Director | 73,247 | Aug 10, 2026 | 3 |
| Jover Placid | See "Remarks" | 6,774 | Aug 5, 2026 | 3 |
| Hughes Eric A | See "Remarks" | 134,877 | Aug 5, 2026 | 5 |
| Shields Matthew | EVP, Global Operations | 0 | Jun 22, 2026 | 4 |
| Kalif Eliyahu Sharon | EVP, Chief Financial Officer | 65,621 | Jun 16, 2026 | 7 |
| Lieberman Gerald M | Director | 130,149 | Jun 8, 2026 | 2 |
| Barer Sol J | Director | 448,011 | Jun 8, 2026 | 2 |
| Crane Rosemary A | Director | 127,739 | Jun 8, 2026 | 2 |
| Francis Richard D | President and CEO | 1,177,529 | Jun 8, 2026 | 6 |
| Nisen Perry | Director | 119,807 | Jun 8, 2026 | 2 |
| Elstein Amir | Director | 2,118,455 | Jun 8, 2026 | 2 |
| Lichtenstein Chen | Director | 19,296 | Jun 8, 2026 | 3 |
| Daniell Richard | EVP, Europe Commercial | 55,755 | May 7, 2026 | 6 |
| Sabag Mark | See "Remarks" | 80,760 | May 4, 2026 | 7 |
| Fox Christine | EVP, U.S. Commercial | 63,647 | May 4, 2026 | 5 |
| McAvoy David R. | EVP, Chief Legal Officer | 13,027 | Sep 9, 2025 | 0 |
| Vergis Janet S. | Director | 73,697 | Jun 9, 2025 | 0 |
| Shalev Varda | Director | 22,504 | Jun 9, 2025 | 0 |
| Grant Angus | EVP, Business Development | 8,848 | Aug 13, 2024 | 0 |
| Conway Vikki L | See "Remarks" | 0 | May 15, 2024 | 0 |
| Drape Eric | Executive VP Global Operations | 145,915 | Mar 7, 2024 | 0 |
| Bergwerk Dov | Acting Chief Legal Officer | 96,983 | Mar 1, 2024 | 0 |
| Stark David Matthew | Exec. VP Chief Legal Officer | 2,974 | Mar 8, 2023 | 0 |
| Dethlefs Sven | EVP, North America Commercial | 165,381 | Mar 8, 2023 | 0 |
| Shani Eli | EVP,Global Marketing&Portfolio | 54,228 | Mar 7, 2023 | 0 |
| Inbar Galia | See "Remarks" | 46,011 | Mar 7, 2023 | 0 |
| Schultz Kare | President and CEO | 1,542,471 | Nov 2, 2022 | 0 |
| Halfon Jean Michel | Director | 63,707 | Aug 8, 2022 | 0 |
| Peres Nechemia Jacob | Director | 58,765 | Aug 8, 2022 | 0 |
| Fridriksdottir Hafrun | Executive VP, Global R&D | 1,387 | May 19, 2022 | 0 |
| Weil Andrew | Chief Accounting Officer | – | Nov 4, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 19, 2022 (view filing) | May 17 | 2 days | Fridriksdottir HafrunExecutive VP, Global R&D | SSale | −130.0K | $8.22 | −$1.07M | −98.9%1.39K after | |
| Mar 8, 2022 (view filing) | Mar 4-7 | 4 days | Stark David MatthewExec. VP Chief Legal Officer | SSale | −32.3K | $7.45 | −$240.7K | −34.6%61.1K after | 3 lots |
| Mar 8, 2022 (view filing) | Mar 4-7 | 4 days | Fridriksdottir HafrunExecutive VP, Global R&D | SSale | −33.6K | $7.45 | −$250.2K | −21.0%126.1K after | 3 lots |
| Mar 8, 2022 (view filing) | Mar 4-7 | 4 days | Drape EricExecutive VP Global Operations | SSale | −34.8K | $7.44 | −$259.0K | −30.8%78.1K after | 3 lots |
| Mar 8, 2022 (view filing) | Mar 4-7 | 4 days | Dethlefs SvenEVP, North America Commercial | SSale | −10.9K | $7.41 | −$80.7K | −6.2%165.4K after | 2 lots |
| Mar 8, 2022 (view filing) | Mar 4-7 | 4 days | Daniell RichardExec. VP, European Commercial | SSale | −59.0K | $7.44 | −$438.5K | −57.7%43.2K after | 3 lots |
| Mar 2, 2022 (view filing) | Feb 28 | 2 days | Stark David MatthewExec. VP Chief Legal Officer | SSale | −6.45K | $8.14 | −$52.5K | −23.2%21.4K after | |
| Mar 2, 2022 (view filing) | Feb 28 | 2 days | Shani EliEVP,Global Marketing&Portfolio | SSale | −5.31K | $8.14 | −$43.2K | −36.9%9.09K after | |
| Mar 2, 2022 (view filing) | Feb 28 | 2 days | Fridriksdottir HafrunExecutive VP, Global R&D | SSale | −7.59K | $8.14 | −$61.8K | −10.4%65.5K after | |
| Mar 2, 2022 (view filing) | Feb 28 | 2 days | Drape EricExecutive VP Global Operations | SSale | −9.80K | $8.14 | −$79.7K | −17.6%45.8K after | |
| Mar 2, 2022 (view filing) | Feb 28 | 2 days | Dethlefs SvenEVP, North America Commercial | SSale | −4.86K | $8.14 | −$39.6K | −4.7%99.5K after | |
| Mar 2, 2022 (view filing) | Feb 28 | 2 days | Daniell RichardExec. VP, European Commercial | SSale | −20.6K | $8.14 | −$167.7K | −50.4%20.3K after | |
| Feb 10, 2022 (view filing) | Feb 9 | 1 day | Stark David MatthewExec. VP Chief Legal Officer | SSale | −6.11K | $9.06 | −$55.4K | −39.4%9.40K after | |
| Feb 10, 2022 (view filing) | Feb 9 | 1 day | Fridriksdottir HafrunExecutive VP, Global R&D | SSale | −6.12K | $9.06 | −$55.4K | −10.6%51.4K after | |
| Feb 10, 2022 (view filing) | Feb 9 | 1 day | Drape EricExecutive VP Global Operations | SSale | −3.58K | $9.06 | −$32.5K | −9.0%36.1K after | |
| Feb 10, 2022 (view filing) | Feb 9 | 1 day | Dethlefs SvenEVP, North America Commercial | SSale | −4.14K | $9.06 | −$37.5K | −4.5%87.0K after | |
| Feb 10, 2022 (view filing) | Feb 9 | 1 day | Daniell RichardExec. VP, European Commercial | SSale | −13.1K | $9.06 | −$119.0K | −39.3%20.3K after | |
| Aug 12, 2021 (view filing) | Aug 10 | 2 days | Fridriksdottir HafrunExecutive VP, Global R&D | SSale | −50.9K | $9.95 | −$506.1K | −55.1%41.4K after |